menu
    • menu

    Company profile for Amphivena Therapeutics

    Rochem, your partner in developing, sourcing, and supplying pharmaceutical & animal health ingredients of Chinese origin.

    Virtual Booth

    Contact Supplier

    DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2025-12-22

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    HTL Biotechnology is a French biotech & a global leader in the responsible development & production of pharma-grade biopolymers.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    REF. STANDARDS & IMPURITIES

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Amphivena Therapeutics Inc is a privately held immuno-oncology company based in SSF, that is developing selective T cell engagers for treatment of hematological and solid tumors. AMV564, our lead molecule, has demonstrated novel clinical activity in rapidly and selectively eliminating leukemic blasts in AML and granulocytic/monocytic MDSCs while sparing normal myeloid cells, providing a unique opportunity to explore the impa...
    Amphivena Therapeutics Inc is a privately held immuno-oncology company based in SSF, that is developing selective T cell engagers for treatment of hematological and solid tumors. AMV564, our lead molecule, has demonstrated novel clinical activity in rapidly and selectively eliminating leukemic blasts in AML and granulocytic/monocytic MDSCs while sparing normal myeloid cells, providing a unique opportunity to explore the impact of depleting MDSCs in cancers.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Amphivena TherapeuticsUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    2 Tower Place South San Francisco, California 94080
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://amphivena.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/amphivena-therapeutics-inc-
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    DCAT Week

    DCAT Week

    Not Confirmed

    envelop Contact Supplier

    DCAT Week

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Amphivena Presents Translational Data Highlighting the Cytokine Profile
    Amphivena Presents Translational Data Highlighting the Cytokine Profile

    13 Apr 2021

    // BUSIESSWIRE

    https://www.businesswire.com/news/home/20210412005256/en/Amphivena-Presents-Translational-Data-Highlighting-the-Cytokine-Profile-for-its-Lead-Clinical-Candidate-AMV564-at-the-AACR-2021-Virtual-Annual-Meeting

    BUSIESSWIRE
    13 Apr 2021
    Share Share
    Amphivena Presents Translational Data Highlighting the Cytokine Profile
    Amphivena Presents Translational Data Highlighting the Cytokine Profile

    13 Apr 2021

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20210412005256/en

    BUSINESSWIRE
    13 Apr 2021
    Share Share
    Amphivena Announces First Patient Dosed in the Phase 1 Dose of AMV564
    Amphivena Announces First Patient Dosed in the Phase 1 Dose of AMV564

    16 Dec 2020

    // BIOSPACE

    https://www.biospace.com/article/releases/amphivena-therapeutics-announces-first-patient-dosed-in-the-phase-1-dose-expansion-of-amv564/

    BIOSPACE
    16 Dec 2020
    Share Share
    Amphivena Presents Clinical Update and Translational Data of AMV564
    Amphivena Presents Clinical Update and Translational Data of AMV564

    09 Nov 2020

    // PRNEWSWIRE

    https://www.prnewswire.com/news-releases/amphivena-presents-clinical-update-and-translational-data-of-amv564-in-solid-tumor-patients-at-the-2020-society-for-immunotherapy-of-cancer-sitc-annual-meeting-301168849.html

    PRNEWSWIRE
    09 Nov 2020
    Share Share
    Amphivena Presents Translational Data for its Lead Clinical Candidate, AMV564
    Amphivena Presents Translational Data for its Lead Clinical Candidate, AMV564

    23 Jun 2020

    // PRNEWSWIRE

    https://www.prnewswire.com/news-releases/amphivena-presents-translational-data-for-its-lead-clinical-candidate-amv564-at-the-aacr-2020-virtual-annual-meeting-ii-301081527.html

    PRNEWSWIRE
    23 Jun 2020
    Share Share
    Amphivena Therapeutics to Present at the Jefferies Virtual Healthcare Conference
    Amphivena Therapeutics to Present at the Jefferies Virtual Healthcare Conference

    29 May 2020

    // PRNEWSWIRE

    https://www.prnewswire.com/news-releases/amphivena-therapeutics-to-present-at-the-jefferies-virtual-healthcare-conference-301067569.html

    PRNEWSWIRE
    29 May 2020
    Share Share

    REF. STANDARDS & IMPURITIES

    Upload your portfolio for free, ask us

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search